Autolus Therapeutics plc
AUTLNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · X0 · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | |
|---|---|---|---|---|
| Revenue | $75.4M | $10.1M | $1.7M | — |
| Operating income | −$270.5M | −$241.4M | −$179.7M | −$36.2M |
| Net income | −$287.5M | −$220.7M | −$208.4M | −$37.1M |
| Total assets | $589.1M | $782.7M | $375.4M | $364.0M |
| Total liabilities | $410.9M | $355.4M | $263.9M | $92.9M |
| Equity | $178.1M | $427.3M | $111.5M | $298.7M |
| EPS (diluted) | $-1.08 | $-0.86 | $-1.20 | $-0.41 |
| Shares out. | 266.1M | 265.9M | 173.9M | 90.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −358.9%
- Net margin
- −381.4%
- Return on equity
- −161.4%
- Return on assets
- −48.8%
- Return on capital (ROCE)
- −52.5%
- Liabilities / assets
- 69.8%
- Debt / equity
- 2.31×
- Book value / share
- $0.67
- Revenue growth (YoY)
- 644.9%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -6.27distress
- Accruals / assets
- −0.7%clean
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 3 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 13, 2024
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Recruitingreadout ~2027-09Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus Erythematosus
- Phase 1Recruitingreadout ~2027-11A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
- Phase 2Recruitingreadout ~2028-08Obe-cel in Severe, Refractory Systemic Lupus Erythematosus With Active Lupus Nephritis
- Phase 1/2Active Not Recruitingreadout ~2029-06-30A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
- Phase 1Recruitingreadout ~2029-08-15Obe-cel in Refractory Progressive Forms of Multiple Sclerosis
- Phase 2Enrolling By Invitationreadout ~2043-07Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Mak Capital Fund LpPassive (13G)May 15, 2026
- Armistice Capital, LlcPassive (13G)May 15, 2026
- Deep Track Capital, LpPassive (13G)Nov 14, 2025
- Wellington Management Group LlpPassive (13G)Oct 6, 2025
- Fmr LlcPassive (13G)May 12, 2025
- Syncona Portfolio LtdPassive (13G)May 7, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 14.0M | 8.6 | +7.1% |
| Apr 30, 2026 | 13.1M | 10.5 | -7.9% |
| Apr 15, 2026 | 14.2M | 10.4 | -2.6% |
| Mar 31, 2026 | 14.6M | 7.2 | -0.8% |
| Mar 13, 2026 | 14.7M | 9.7 | -1.8% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operations · Regulation FD disclosureMay 14, 2026
- Costs from exit or disposal · Regulation FD disclosureApr 29, 2026
- Changed auditorApr 16, 2026
- Regulation FD disclosureApr 8, 2026
- Results of operations · Regulation FD disclosureMar 27, 2026
- Entered a material agreementJan 26, 2026
- Regulation FD disclosure · Other material eventJan 12, 2026
- Director / officer change · Regulation FD disclosureDec 2, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.